These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 39114870)

  • 1. A plain language summary of the results from the phase 2b HERIZON-BTC-01 study of zanidatamab in participants with HER2-amplified biliary tract cancer.
    Harding JJ; Fan J; Oh DY; Choi HJ; Kim JW; Chang HM; Bao L; Sun HC; Macarulla T; Xie F; Metges JP; Ying J; Bridgewater J; Lee MA; Tejani MA; Chen EY; Kim DU; Wasan H; Ducreux M; Bao Y; Lindsey S; Bachini M; Morement H; Boyken L; Ma J; Garfin P; Pant S;
    Future Oncol; 2024; 20(31):2319-2329. PubMed ID: 39114870
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study.
    Harding JJ; Fan J; Oh DY; Choi HJ; Kim JW; Chang HM; Bao L; Sun HC; Macarulla T; Xie F; Metges JP; Ying J; Bridgewater J; Lee MA; Tejani MA; Chen EY; Kim DU; Wasan H; Ducreux M; Bao Y; Boyken L; Ma J; Garfin P; Pant S;
    Lancet Oncol; 2023 Jul; 24(7):772-782. PubMed ID: 37276871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study.
    Meric-Bernstam F; Beeram M; Hamilton E; Oh DY; Hanna DL; Kang YK; Elimova E; Chaves J; Goodwin R; Lee J; Nabell L; Rha SY; Mayordomo J; El-Khoueiry A; Pant S; Raghav K; Kim JW; Patnaik A; Gray T; Davies R; Ozog MA; Woolery J; Lee KW
    Lancet Oncol; 2022 Dec; 23(12):1558-1570. PubMed ID: 36400106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HERIZON-GEA-01: Zanidatamab + chemo ± tislelizumab for 1L treatment of HER2-positive gastroesophageal adenocarcinoma.
    Tabernero J; Shen L; Elimova E; Ku G; Liu T; Shitara K; Lin X; Boyken L; Li H; Grim J; Ajani J
    Future Oncol; 2022 Sep; 18(29):3255-3266. PubMed ID: 36000541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study.
    Javle M; Borad MJ; Azad NS; Kurzrock R; Abou-Alfa GK; George B; Hainsworth J; Meric-Bernstam F; Swanton C; Sweeney CJ; Friedman CF; Bose R; Spigel DR; Wang Y; Levy J; Schulze K; Cuchelkar V; Patel A; Burris H
    Lancet Oncol; 2021 Sep; 22(9):1290-1300. PubMed ID: 34339623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase 2 trial of zanidatamab in HER2-overexpressed advanced endometrial carcinoma and carcinosarcoma (ZW25-IST-2).
    Lumish M; Chui MH; Zhou Q; Iasonos A; Sarasohn D; Cohen S; Friedman C; Grisham R; Konner J; Kyi C; Rubinstein M; Troso-Sandoval T; Aghajanian C; Makker V
    Gynecol Oncol; 2024 Mar; 182():75-81. PubMed ID: 38262242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overexpression and gene amplification of EGFR, HER2, and HER3 in biliary tract carcinomas, and the possibility for therapy with the HER2-targeting antibody pertuzumab.
    Kawamoto T; Ishige K; Thomas M; Yamashita-Kashima Y; Shu S; Ishikura N; Ariizumi S; Yamamoto M; Kurosaki K; Shoda J
    J Gastroenterol; 2015 Apr; 50(4):467-79. PubMed ID: 25112701
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pertuzumab Plus Trastuzumab in Patients With Biliary Tract Cancer With
    Cannon TL; Rothe M; Mangat PK; Garrett-Mayer E; Chiu VK; Hwang J; Vijayvergia N; Alese OB; Dib EG; Duvivier HL; Klute KA; Sahai V; Ahn ER; Bedano P; Behl D; Sinclair S; Thota R; Urba WJ; Yang ES; Grantham GN; Hinshaw DC; Gregory A; Halabi S; Schilsky RL
    J Clin Oncol; 2024 Sep; 42(27):3228-3237. PubMed ID: 38748939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EGFR, HER2, and MET gene amplification and protein expression profiles in biliary tract cancer and their prognostic significance.
    Kim Y; Jee S; Kim H; Paik SS; Choi D; Yoo SH; Shin SJ
    Oncologist; 2024 Aug; 29(8):e1051-e1060. PubMed ID: 38709907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Co-clinical Trial of Novel Bispecific Anti-HER2 Antibody Zanidatamab in Patient-Derived Xenografts.
    DiPeri TP; Evans KW; Wang B; Zhao M; Akcakanat A; Raso MG; Rizvi YQ; Zheng X; Korkut A; Varadarajan K; Uzunparmak B; Dumbrava EE; Pant S; Ajani JA; Pohlmann PR; Jensen VB; Javle M; Rodon J; Meric-Bernstam F
    Cancer Discov; 2024 May; 14(5):828-845. PubMed ID: 38358339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population pharmacokinetics of zanidatamab, an anti-HER2 biparatopic antibody, in patients with advanced or metastatic cancer.
    Proctor JR; Gartner EM; Gray TE; Davies RH
    Cancer Chemother Pharmacol; 2022 Nov; 90(5):399-408. PubMed ID: 36102999
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brightline-2: a phase IIa/IIb trial of brigimadlin (BI 907828) in advanced biliary tract cancer, pancreatic ductal adenocarcinoma or other solid tumors.
    Yoo C; Lamarca A; Choi HJ; Vogel A; Pishvaian MJ; Goyal L; Ueno M; Märten A; Teufel M; Geng L; Morizane C
    Future Oncol; 2024; 20(16):1069-1077. PubMed ID: 38214149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trastuzumab deruxtecan in previously treated HER2-positive metastatic breast cancer: Plain language summary of the DESTINY-Breast01 study.
    Modi S
    Future Oncol; 2021 Sep; 17(26):3415-3423. PubMed ID: 34263665
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A plain language summary of the TROPHY-U-01 study: sacituzumab govitecan use in people with locally advanced or metastatic urothelial cancer.
    Loriot Y; Kalebasty AR; Fléchon A; Jain RK; Gupta S; Bupathi M; Beuzeboc P; Palmbos P; Balar AV; Kyriakopoulos CE; Pouessel D; Sternberg CN; Tonelli J; Sierecki M; Zhou H; Grivas P; Barthélémy P; Bangs R; Tagawa ST
    Future Oncol; 2024; 20(23):1621-1631. PubMed ID: 38682560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Addition of ramucirumab or merestinib to standard first-line chemotherapy for locally advanced or metastatic biliary tract cancer: a randomised, double-blind, multicentre, phase 2 study.
    Valle JW; Vogel A; Denlinger CS; He AR; Bai LY; Orlova R; Van Cutsem E; Adeva J; Chen LT; Obermannova R; Ettrich TJ; Chen JS; Wasan H; Girvan AC; Zhang W; Liu J; Tang C; Ebert PJ; Aggarwal A; McNeely SC; Moser BA; Oliveira JM; Carlesi R; Walgren RA; Oh DY
    Lancet Oncol; 2021 Oct; 22(10):1468-1482. PubMed ID: 34592180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plain language summary of the TOPAZ-1 study: durvalumab and chemotherapy for advanced biliary tract cancer.
    Oh DY; He AR; Qin S; Chen LT; Okusaka T; Vogel A; Kim JW; Suksombooncharoen T; Lee MA; Kitano M; Burris H; Bouattour M; Tanasanvimon S; McNamara MG; Zaucha R; Avallone A; Tan B; Cundom J; Lee CK; Takahashi H; Ikeda M; Chen JS; Wang J; Makowsky M; Rokutanda N; Żotkiewicz M; Kurland JF; Cohen G; Valle JW
    Future Oncol; 2023 Nov; 19(34):2277-2289. PubMed ID: 37746835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trastuzumab Deruxtecan in Human Epidermal Growth Factor Receptor 2-Expressing Biliary Tract Cancer (HERB; NCCH1805): A Multicenter, Single-Arm, Phase II Trial.
    Ohba A; Morizane C; Kawamoto Y; Komatsu Y; Ueno M; Kobayashi S; Ikeda M; Sasaki M; Furuse J; Okano N; Hiraoka N; Yoshida H; Kuchiba A; Sadachi R; Nakamura K; Matsui N; Nakamura Y; Okamoto W; Yoshino T; Okusaka T
    J Clin Oncol; 2024 Sep; 42(27):3207-3217. PubMed ID: 39102634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic implication of HER2 in advanced biliary tract cancer.
    Nam AR; Kim JW; Cha Y; Ha H; Park JE; Bang JH; Jin MH; Lee KH; Kim TY; Han SW; Im SA; Kim TY; Oh DY; Bang YJ
    Oncotarget; 2016 Sep; 7(36):58007-58021. PubMed ID: 27517322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Zolbetuximab plus chemotherapy for locally advanced unresectable or metastatic stomach or gastroesophageal junction cancers: a plain language summary.
    Shitara K; Shah MA; Lordick F; Bang YJ; Ilson D; Van Cutsem E; Enzinger P; Kim SS; Klempner SJ; Moran D; Park JW; Bhattacharya P; Ajani JA; Xu RH
    Future Oncol; 2024; 20(26):1861-1877. PubMed ID: 38861294
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study.
    Meric-Bernstam F; Hurwitz H; Raghav KPS; McWilliams RR; Fakih M; VanderWalde A; Swanton C; Kurzrock R; Burris H; Sweeney C; Bose R; Spigel DR; Beattie MS; Blotner S; Stone A; Schulze K; Cuchelkar V; Hainsworth J
    Lancet Oncol; 2019 Apr; 20(4):518-530. PubMed ID: 30857956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.